Download PDF
Dtsch Med Wochenschr 2004; 129(45): 2429-2433
DOI: 10.1055/s-2004-835284
Übersichten
Hämatologie/Onkologie
© Georg Thieme Verlag Stuttgart · New York

Aktuelle Therapiestrategien beim fortgeschrittenen Mantelzell-Lymphom

Current strategies in the treatment of advanced stage mantle cell lymphomaG. Lenz1 , M. Dreyling1 , M. Unterhalt1 , W. Hiddemann1
  • 1Medizinische Klinik III, Klinikum der Ludwig Maximilians-Universität, München.
Further Information

Publication History

eingereicht: 3.6.2004

akzeptiert: 8.9.2004

Publication Date:
04 November 2004 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Mit einem medianen Überleben von nur 3 Jahren weisen fortgeschrittene Mantelzell-Lymphome die schlechteste Langzeitprognose aller Lymphomsubtypen auf und sind mittels konventioneller Chemotherapie nicht heilbar. Zwei aktuelle Studien der Deutschen Studiengruppe für niedrig-maligne Lymphome (GLSG) zeigen den Vorteil einer kombinierten Immunochemotherapie mit dem Anti-CD20-Antikörper Rituximab sowohl in der Primärtherapie (R-CHOP) als auch im Rezidiv (R-FCM). Zusätzlich konnte in einer multizentrischen Studie des Europäischen Mantelzell-Lymphom-Netzwerkes durch eine konsolidierende Hochdosistherapie mit nachfolgender autologer Stammzelltransplantation das progressionsfreie Überleben bei Patienten unter 66 Jahren signifikant verlängert werden. Trotzdem erleidet ein Großteil der Patienten mit Mantelzell-Lymphom auch nach einer solchen dosisgesteigerten Therapie ein Rezidiv. Daher ist die Erprobung neuer Strategien wie die allogene Stammzelltransplantation nach Dosis-reduzierter Konditionierung und die Entwicklung neuer Substanzen (z. B. Proteosomeninhibitoren oder Radioimmunotherapie) dringend erforderlich, um die Langzeitprognose des Mantelzell-Lymphoms weiter zu verbessern.

Summary

Advanced stage mantle cell lymphoma (MCL) with a median survival of only three years and virtually no long-term survivors represents the lymphoma subtype with the poorest prognosis and remains incurable with conventional chemotherapy. Recently two randomized trials of the German Low Grade Lymphoma Study Group (GLSG) demonstrated the superiority of a combined immunochemotherapy with the anti-CD20 antibody rituximab in first-line therapy (R-CHOP) as well as in relapsed disease (R-FCM). In addition, in a trial of the European MCL Network, intensified-consolidation with high-dose radiochemotherapy followed by autologous stem cell transplantation significantly improved the progression-free survival in patients up to 65 years of age. However, the vast majority of patients with MCL will eventually relapse. Thus, new strategies such as allogenic transplantation after dose-reduced conditioning or novel molecular targeting agents (e. g. proteasome inhibitors or radiolabeled antibodies) are urgently warranted to further improve the long-term outcome of MCL.

Literatur

  • 1 The International Non-Hodgkin’s Lymphoma Prognostic Factors Project . A predictive model for aggressive non-Hodgkin’s lymphoma.  N Engl J Med. 1993;  329 987-994
    Google Scholar
  • 2 Adkins D, Brown R, Goodnough L T, Khoury H, Popovic W, DiPersio J. Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation.  Bone Marrow Transplant. 1998;  21 97-99
    Google Scholar
  • 3 Andersen N S, Pedersen L, Elonen E. et al . Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant.  Eur J Haematol. 2003;  71 73-80
    Google Scholar
  • 4 Argatoff L H, Connors J M, Klasa R J, Horsman D E, Gascoyne R D. Mantle cell lymphoma: a clinicopathologic study of 80 cases.  Blood. 1997;  89 2067-2078
    Google Scholar
  • 5 Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.  Blood. 1999;  94 2836-2843
    Google Scholar
  • 6 Berdeja J G, Jones R J, Zahurak M L. et al . Allogeneic bone marrow transplantation in patients with sensitive low- grade lymphoma or mantle cell lymphoma.  Biol Blood Marrow Transplant. 2001;  7 561-567
    Google Scholar
  • 7 Brugger W, Hirsch J, Repp R, Grünebach F, Schlimok G. Treatment of Follicular and Mantle cell lymphoma with Rituximab after High-dose chemotherapy and autologous blood stem cell Transplantation: A multicenter phase II study (abstract).  Blood. 2002;  100 644a
    Google Scholar
  • 8 Campo E, Raffeld M, Jaffe E S. Mantle-cell lymphoma.  Semin Hematol. 1999;  36 115-127
    Google Scholar
  • 9 Cohen B J, Moskowitz C, Straus D, Noy A, Hedrick E, Zelenetz A. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.  Leuk Lymphoma. 2001;  42 1015-1022
    Google Scholar
  • 10 Coiffier B, Haioun C, Ketterer N. et al . Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.  Blood. 1998;  92 1927-1932
    Google Scholar
  • 11 Decaudin D, Bosq J, Tertian G. et al . Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.  J Clin Oncol. 1998;  16 579-583
    Google Scholar
  • 12 Drach J, Kaufmann H, Puespoek A. et al . Marked anti-tumor activity of rituximab plus Thalidomide in patients with relapsed/resistant mantle cell lymphoma (abstract).  Blood. 2002;  100 606
    Google Scholar
  • 13 Dreger P, Martin S, Kuse R. et al . The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.  Hematol J. 2000;  1 87-94
    Google Scholar
  • 14 Foran J M, Rohatiner A Z, Coiffier B. et al . Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom’s macroglobulinemia, and mantle-cell lymphoma.  J Clin Oncol. 1999;  17 546-553
    Google Scholar
  • 15 Foran J M, Rohatiner A Z, Cunningham D. et al . European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.  J Clin Oncol. 2000;  18 317-324
    Google Scholar
  • 16 Forstpointner R, Dreyling M, Repp R. et al . The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German low grade lymphoma study group (GLSG).  Blood. 2004;  in press
    Google Scholar
  • 17 Ghielmini M, Schmitz S F, Burki K. et al . The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK).  Ann Oncol. 2000;  11 123-126
    Google Scholar
  • 18 Gianni A M, Magni M, Martelli M. et al . Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).  Blood. 2003;  102 749-755
    Google Scholar
  • 19 Gopal A K, Rajendran J G, Petersdorf S H. et al . High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.  Blood. 2002;  99 3158-3162
    Google Scholar
  • 20 Goy A, Hart S, Pro B. et al . Report of a phase II study of proteasome inhibitor Bortezombin (Velcade) in patients with relapsed or refractory indolent or aggressive Lymphomas (abstract).  Blood. 2003;  102 627
    Google Scholar
  • 21 Hiddemann W, Unterhalt M, Herrmann R. et al . Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.  J Clin Oncol. 1998;  16 1922-1930
    Google Scholar
  • 22 Hiddemann W, Dreyling M H, Pfreundschuh M. et al . Myeloablative Radiochemotherapy followed by autologous Blood stem cell transplantation leads to a significant prolongation of the event-free survival in patients with mantle cell lymphoma (MCL) - results of a prospective randomized European Intergruoup study (abstract).  Blood. 2001;  98 861
    Google Scholar
  • 24 Hiddemann W, Unterhalt M, Dreyling M H. et al . The addition of Rituximab (R) to Combination Chemotherapy (CT) significantly improves the treatment of Mantle cell lymphoma (MCL): Results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG) (abstract).  Blood. 2002;  100 339
    Google Scholar
  • 25 Howard O M, Gribben J G, Neuberg D S. et al . Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.  J Clin Oncol. 2002;  20 1288-1294
    Google Scholar
  • 26 Jaffe E S, Harris N L, Stein H, Vardiman J. World Health Organization Classification of Tumours: Tumours of the Haemopoitic and Lymphoid Tissues. IARC Press, Lyon 2001
    Google Scholar
  • 27 Koehl U, Li L, Nowak B. et al . Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross-link removal (abstract).  Proceedings ASCO. 1997;  38 A10
    Google Scholar
  • 28 Kroger N, Hoffknecht M, Kruger W. et al . Allogeneic bone marrow transplantation for refractory mantle cell lymphoma.  Ann Hematol. 2000;  79 578-580
    Google Scholar
  • 29 Lefrere F, Delmer A, Suzan F. et al . Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.  Leukemia. 2002;  16 587-593
    Google Scholar
  • 30 Leitch H A, Gascoyne R D, Chhanabhai M, Voss N J, Klasa R, Connors J M. Limited-stage mantle-cell lymphoma.  Ann Oncol. 2003;  14 1555-1561
    Google Scholar
  • 31 Lenz G, Unterhalt M, Haferlach T, Hiddemann W, Dreyling M H. Significant increase of secondary myelodysplasia and acute myeloid leukemia after myeloablative radiochemotherapy followed by autologous stem cell transplantation in indolent lymphoma patients - results of a prospective randomized study for the GLSG (abstract).  Blood. 2003;  102 986
    Google Scholar
  • 32 Magni M, Di Nicola M, Devizzi L. et al . Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.  Blood. 2000;  96 864-869
    Google Scholar
  • 33 Martinez C, Carreras E, Rovira M. et al . Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation.  Bone Marrow Transplant. 2000;  26 677-679
    Google Scholar
  • 34 Meusers P, Engelhard M, Bartels H. et al . Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis.  Hematol Oncol. 1989;  7 365-380
    Google Scholar
  • 35 Meusers P, Hense J, Brittinger G. Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems.  Leukemia. 1997;  11 (Suppl 2) S60-S64
    Google Scholar
  • 36 Nguyen D T, Amess J A, Doughty H, Hendry L, Diamond L W. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low- grade non-Hodgkin’s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients.  Eur J Haematol. 1999;  62 76-82
    Google Scholar
  • 37 Romaguera J E, Khouri I F, Kantarjian H M. et al . Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients.  Leuk Lymphoma. 2000;  39 77-85
    Google Scholar
  • 38 Rummel M, Chow K, Karakas T. et al . Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin’s lymphoma.  Eur J Cancer. 2002;  38 1739
    Google Scholar
  • 39 Stewart D A, Vose J M, Weisenburger D D. et al . The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma.  Ann Oncol. 1995;  6 263-266
    Google Scholar
  • 40 Teodorovic I, Pittaluga S, Kluin-Nelemans J C. et al . Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin’s lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.  J Clin Oncol. 1995;  13 2819-2826
    Google Scholar
  • 41 Tobinai K. Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan.  Int J Hematol. 2002;  76 411-419
    Google Scholar
  • 42 Touati M, Fitoussi O, Jaccard A, Petit B. DHAP regimen for relapsed or refractory low grade Lymphomas: A study of 86 cases (abstract).  Blood. 2002;  100 302b
    Google Scholar
  • 43 Unterhalt M, Herrmann R, Tiemann M. et al . Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin’s lymphoma. German Low-Grade Lymphoma Study Group.  Leukemia. 1996;  10 836-843
    Google Scholar
  • 44 Vandenberghe E, De Wolf-Peeters C, Vaughan Hudson G. et al . The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group.  Br J Haematol. 1997;  99 842-847
    Google Scholar
  • 45 Vandenberghe E, Ruiz de Elvira C, Loberiza F R. et al . Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries.  Br J Haematol. 2003;  120 793-800
    Google Scholar
  • 46 Younes A, Pro B, Delpassand E, McLaughlin P, Romaguera J, Wang M. A phase II study of 90Yttrium-ibritumomab (Zevalin) for the treatment of patients with relapsed and refractory Mantle cell lymphoma (MCL) (abstract).  Blood. 2003;  102 1476
    Google Scholar
  • 47 Zinzani P L, Magagnoli M, Moretti L. et al . Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.  J Clin Oncol. 2000;  18 773-779
    Google Scholar
  • 48 Zucca E, Roggero E, Pinotti G. et al . Patterns of survival in mantle cell lymphoma.  Ann Oncol. 1995;  6 257-262
    Google Scholar

Dr. Georg Lenz

Medizinische Klinik III, Klinikum der Ludwig-Maximilians Universität München

Marchioninistraße 15

81377 München

Phone: 089/70950

Fax: 089/70955550

Email: georg.lenz@med.uni-muenchen.de

      >